T his past March, FDA approved two new oral drug treatmentssiponimod (Mayzent-Novartis) and cladribine (Mavenclad-EMD Serono)-for relapsing forms of multiple sclerosis (MS), including active secondary progressive MS (SPMS). Of the more than a dozen diseasemodifying therapies approved by the agency for relapsing forms of MS, siponimod and cladribine are currently the only oral drugs specifically approved for treatment of active SPMS. The drug approvals are significant breakthroughs in the development of additional therapeutic options for patients living with the disease. "Multiple sclerosis can have a profound impact on a person's life," said Billy Dunn, MD, director of the Division of Neurology Products in FDA's Center for Drug Evaluation and Research, in a statement. "We are committed to supporting the development of safe and effective treatments for patients with [this disease]."
Siponimod (Mayzent-Novartis)
Siponimod is a sphingosine 1-phosphate receptor modulator that prevents lymphocytes from entering lymph nodes and the central nervous system (CNS).
It is indicated for treatment of relapsing forms of MS in adults, including active SPMS, relapsingremitting MS (RRMS), and clinically isolated syndrome (CIS). Siponimod was the first oral drug approved to treat active SPMS.
Phase III EXPAND trial
FDA's approval of the drug was based on the results of the Phase III EXPAND (Exploring the Efficacy and Safety of Siponimod in Patients with Secondary Progressive Multiple Sclerosis) trial, the largest randomized, double-blind, placebo-controlled study on SPMS to date, consisting of 1,651 patients with SPMS from 31 countries.
On average, the study participants were aged 48 years and had been living with MS for approximately 16 years. More than one-half had a median Expanded Disability Status Scale (EDSS) score of 6.0 and relied on a walking aid.
The study showed that siponimod significantly reduced the risk of 3-month confirmed disability progression (CDP) by 21% and 6-month CDP by 26% compared with placebo. In addition, the drug reduced the annualized relapse rate in these patients by 55%.
Compared with placebo, more patients treated with siponimod were free from gadolinium-enhancing lesions (89%) and new or enlarging T2 lesions (57%). These patients also showed favorable outcomes in cognition, MRI disease activity, and brain volume loss.
"With the approval of [siponimod], we now have a much-needed therapeutic option to address SPMS with active disease," said EXPAND steering committee member Bruce Cree, MD, PhD, MAS, clinical research director and George A. Zimmermann Endowed Professor in Multiple Sclerosis, at the University of California, San Francisco, School of Medicine, in a statement.
What you should know
Before starting treatment with siponimod, providers should determine patients' CYP2C9 genotype, as the type of CYP2C9 variant may determine recommended maintenance dosage (see sidebar). The drug should not be used by patients who have a CYP2C9*3/*3 genotype.
Providers should assess patients' recent transaminase and bilirubin levels, as well as obtain complete blood count (CBC) and ECG results before initiation of treatment. Advice from a cardiologist and first-dose monitoring are recommended in patients with certain pre-existing conditions.
Patients who have experienced at least one of the following in the previous 6 months should not use siponimod: Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or class III or IV heart failure.
Pharmacists should review patients' medication history before starting treatment with siponimod. Current or prior use of antineoplastic, immunosuppressive, or immune-modulating therapies may cause unintended additional immunosuppressive effects.
What your patients should know
The most common adverse effects of siponimod are headache, hypertension, and transaminase increase.
Pharmacists Advise patients-especially those with diabetes or a history of uveitisto contact their physician if they experience changes in vision, as the drug may cause macular edema. The drug may also increase liver enzymes, so it is important to inform patients to contact their physician if they experience any signs of liver injury, including unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, jaundice, and dark urine.
Emphasize to patients of childbearing potential that siponimod may cause fetal harm. These patients should use effective contraception during treatment and for 10 days after stopping treatment.
Cladribine (Mavenclad-EMD Serono)
Cladribine is a purine antimetabolite oral tablet that reduces the damaging immune response-in which the immune system mistakenly attacks the CNS-seen in MS. The drug interferes with DNA repair and replication of Band T-cells, subsequently leading to the immune cells' deaths and reduced number in the bloodstream.
The drug is indicated for treatment of relapsing forms of MS in adults, including RRMS and active SPMS. Unlike siponimod, however, it is not recommended for patients with CIS.
Because of its safety profile, cladribine is recommended as an option for patients who have not responded to, or are unable to tolerate, alternate treatments for MS.
Phase III CLARITY trial
Cladribine's FDA approval was based on the Phase III CLARITY (A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis) trial, which involved 1,326 patients with relapsing forms of MS who experienced at least one relapse in the previous 12 months.
The study randomized the participants to receive one of two doses of cladribine (either 3.5 mg/kg or 5.25 mg/kg) or placebo. Compared with the placebo group, the drug significantly reduced the number of relapses experienced by these patients by more than 50%, as well as lowered their risk of 3-month sustained disability progression (for the 3.5-mg group: hazard ratio 0.67 [95% CI 0.48-0.93], P = 0.02; for the 5.25-mg group: 0.69 [0.49-0.96], P = 0.03).
What you should know
Cladribine has a boxed warning for increased risk of malignancy and fetal harm. Patients with current malignancy should not use this drug. Health care providers should determine if the benefits of cladribine outweigh its risks in patients who have had prior malignancy or have an increased risk of developing malignancy.
Because cladribine may decrease lymphocyte counts and may cause hematologic toxicity and bone marrow suppression, health care providers should measure patients' lymphocyte counts and CBC before, during, and after treatment. The drug has also been associated with graft-versus-host disease following blood transfusions with nonirradiated blood.
What your patients should know
Cladribine's most common adverse effects include upper respiratory tract infections, headache, and decreased lymphocyte counts.
Caution patients against using cladribine if they are pregnant or planning to become pregnant. Because the drug may cause fetal harm, encourage individuals of childbearing potential to use effective contraception during treatment and for at least 6 months after the last dose in each treatment course.
Instruct female patients and male patients with female partners to immediately inform their health care provider if pregnancy occurs during cladribine treatment. In addition, women should not breastfeed on the day of treatment and for 10 days after the last dose.
Inform patients that the drug may also increase the risk of infections, as well as liver injury and heart failure. Advise patients to promptly report any signs of these conditions to their health care provider. Providers should stop treatment if significant liver injury or heart failure is suspected.
Pharmacists should inform patients that cladribine is cytotoxic. Patients should handle the drug with care, limit direct skin contact with the tablets, and wash exposed areas thoroughly. Pharmacists should also advise patients on the proper ways to dispose of any unused tablets. Because of its safety profile, the drug is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug for MS treatment. Dosage: Cumulative dosage is 3.5 mg/kg, administered orally and divided into two yearly treatment courses (1.75 mg/kg per treatment course). Each treatment course is divided into two treatment cycles. Separate administration from any other oral drug by at least 3 hours. Of note: Cladribine is not indicated for patients with clinically isolated syndrome.
The drug has a boxed warning for an increased risk of malignancy and fetal harm. Cladribine should not be used with immunosuppressive, antiviral, and antiretroviral drugs, as well as breast cancer resistance protein (BCRP) inhibitors or equilibrative nucleoside transporters/concentrative nucleoside transporter (ENT/CNT) inhibitors. The drug is cytotoxic and must be handled carefully, with limited direct skin contact with the tablets.
